Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
![Business Wire](../../../Content/images/providers/BW.png)
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer. Members of Tempus’ commercial team can now engage in discussions with doctors about the use of the NeXT Personal Dx test for breast and lung cancers, and for immunotherapy monitoring across all solid tumors.“Today’s announcement opens up new possibilities for cancer patients and we’re excited to be working with Tempus to reach oncologists through our collective efforts,” said Chris Hall, CEO, Personalis.This announcement follows the launch of NeXT Personal Dx in early access last October. NeXT Personal Dx helps oncologists detect cancer recurrence earlier and aids in treatment decision-making, with the ability to detect in blood jus
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.MarketBeat
- Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference [Yahoo! Finance]Yahoo! Finance
- Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution ConferenceBusiness Wire
- Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call [Yahoo! Finance]Yahoo! Finance
- Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference CallBusiness Wire
PSNL
Earnings
- 5/8/24 - Beat
PSNL
Sec Filings
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- PSNL's page on the SEC website